Web site after the meeting, at http://healthit.hhs.gov.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the workgroups. Written submissions may be made to the contact person on or before two days prior to the workgroup’s meeting date. Oral comments from the public will be scheduled at the conclusion of each workgroup meeting. Time allotted for each presentation will be limited to three minutes. If the number of speakers requesting to comment is greater than can be reasonably accommodated during the scheduled open public session, ONC will take written comments after the meeting until close of business on that day.

Persons attending ONC’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. ONC welcomes the attendance of the public at its advisory committee meetings. Seating is limited at the location, and ONC will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Mary Jo Deering at least seven (7) days in advance of the meeting.

ONC is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at http://healthit.hhs.gov for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (Pub. L. 92–463, 5 U.S.C., App. 2).

Dated: March 8, 2012.

Mary Jo Deering,
Office of Policy and Planning, Office of the National Coordinator for Health Information Technology

[FR Doc. 2012–6437 Filed 3–15–12; 8:45 am]
BILLING CODE 4150–28–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Office of the Assistant Secretary for Health, Statement of Organization, Functions, and Delegation of Authority

Part A. Office of the Secretary, Statement of Organization, Functions, and Delegation of Authority for the U.S. Department of Health and Human Services is being amended at Chapter AC, Office of the Assistant Secretary for Health (OASH), as last amended at 60 FR 56605–06, dated November 9, 1995; 60 FR 59410, dated February 14, 1995; and most recently at 75 FR 53304–05, dated August 31, 2010, as follows:

1. Under Chapter AC, delete Paragraph H, “Office of HIV/AIDS Policy (ACJ),” in its entirety and replace with the following:

H. Office of HIV/AIDS and Infectious Disease Policy (ACJ)

The Office of HIV/AIDS and Infectious Disease Policy (OHAIIDP) is under the direction of the Deputy Assistant Secretary for Health, Infectious Diseases, who serves as the Director of the Office of HIV/AIDS and Infectious Disease Policy, and as the principal advisor to the Assistant Secretary for Health (ASH) and the Secretary on health policy and program issues related to HIV disease and infectious diseases of public health significance. These issues cut across Health and Human Services (HHS) components which provide research, services, prevention, treatment, and education and information dissemination to susceptible populations.

OHAIIDP is responsible for coordinating, integrating, and directing the Department’s policies, programs, and activities related to HIV/AIDS, viral hepatitis, other infectious diseases of public health significance, and blood safety and availability. The Office: (1) Facilitates and/or coordinates policy planning processes related to infectious diseases, including viral hepatitis and HIV/AIDS, across HHS and monitors progress toward achieving established goals; (2) Advises on issues related to blood and blood products; (3) Monitors the implementation of the National HIV/AIDS Strategy across HHS; (4) Identifies critical HIV/AIDS policy issues, including the inter-and intra-agency coordination need, and advises on how best to address/resolve these issues; (5) Serves as HHS liaison with the Office of the National AIDS Policy Coordinator, Executive Office of the President; (6) Assists in the preparation of responses to inquiries regarding programs and policies intended to promote effective prevention and advancement of research for HIV/AIDS, viral hepatitis, and other infectious diseases of public health significance; (7) Provides liaison with other Federal organizations involved in addressing HIV/AIDS, viral hepatitis and/or other infectious diseases of public health significance; (8) Provides analytic and administrative support to the Advisory Committee on Blood Safety and Availability (ACBSA), the Presidential Advisory Council on HIV/AIDS (PACHA), cross-Departmental, coordinating groups, and other subsidiary or independent task forces, work groups, or subgroups; (9) Provides guidance on the cooperative dissemination and exchange of scientific, prevention, educational information, and clinical guidelines related to public health interest groups, health professional, and private sector organizations; (10) Guides, supports, and promotes methods of dissemination and exchange of information to and among the public; (11) Reviews and makes recommendations on ONC budget requests related to departmental research, prevention, services, training, information, and infrastructure priorities as incorporated in planning documents or budget proposals.

II. Delegations of Authority. Pending further re-delegation, directives or orders made by the Secretary, the Assistant Secretary for Health, or the Deputy Assistant Secretary for Health, Infectious Diseases, all delegations and re-delegations of authority made to officials and employees of the affected organizational component will continue in them pending further re-delegations, provided they are consistent with this reorganization.

Dated: March 6, 2012.

E.J. Holland, Jr.,
Assistant Secretary for Administration.

[FR Doc. 2012–6466 Filed 3–15–12; 8:45 am]
BILLING CODE 4150–28–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Subcommittee on Procedures Review, Advisory Board on Radiation and Worker Health (ABRW), National Institute for Occupational Safety and Health (NIOSH)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting for the aforementioned subcommittee:

Time and Date: 9 a.m.–5 p.m., April 11, 2012.

Place: Cincinnati Airport Marriott, 2395 Progress Drive, Hebron, Kentucky 41018, Telephone (859) 334–4611, Fax (859) 334–4610.

Status: Open to the public, but without a verbal public comment period. Written comment should be provided to the contact person below in advance of the meeting. To access by conference call dial the following information 1 (866) 659–0537, Participant Pass Code 9933701.

Background: The ABRWH was established under the Energy Employees Occupational Illness Compensation Program Act of 2000 to advise the President on a variety of policy and technical functions required to implement and effectively manage the
compensation program. Key functions of the ABRWH include providing advice on the development of probability of causation guidelines that have been promulgated by the Department of Health and Human Services (HHS) as a final rule; advice on methods of dose reconstruction which have also been promulgated by HHS as a final rule; advice on the scientific validity and quality of dose estimation and reconstruction efforts being performed for purposes of the compensation program; and advice on petitions to add classes of workers to the Special Exposure Cohort (SEC).

In December 2000, the President delegated responsibility for funding, staffing, and operating the ABRWH to HHS, which subsequently delegated this authority to CDC. NIOSH implements staffing, and operating the ABRWH to classes of workers to the Special Reconstruction at Uranium Facilities'' (OTIB–0054 ("Fission and Activation Product Assignment for Internal Dose-Related Gross Beta and Gross Gamma Analyses"), and PER 20 ("Blockson TBD Revision"): Identification of Overarching Dose Reconstruction Issues; Discussion of Completed Procedure Reviews for Summarization; and a continuation of the comment-resolution process for other dose reconstruction procedures under review by the Subcommittee.

The agenda is subject to change as priorities dictate.

In the event an individual cannot attend, written comments may be submitted. Any written comments received will be provided at the meeting and should be submitted to the contact person below well in advance of the meeting.

Contact Person for More Information: Theodore Katz, Executive Secretary, NIOSH, CDC, 1600 Clifton Road NE., Mailstop E–20, Atlanta, Georgia 30333, Telephone (513) 533–6800, Toll Free 1 (900) CDC–INFO, Email dcas@cdc.gov.

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: March 9, 2012.

John Kastenbauer,
Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2012–6475 Filed 3–15–12; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2011–N–0627]

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; General Administrative Procedures: Citizen Petitions; Petition for Reconsideration or Stay of Action; Advisory Opinions

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

DATES: Fax written comments on the collection of information by April 16, 2012.

ADDRESSES: To ensure that comments on this information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, FAX: 202–395–7285, or emailed to oira_submission@omb.eop.gov. All comments should be identified with the OMB control number 0910–0183. Also include the FDA docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Ila S. Mizrachi, Office of Information Management, Food and Drug Administration, 1350 Piccard Dr., PI50–400B, Rockville, MD 20850, 301–796–7726, Ilamizrachi@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

General Administrative Procedures: Citizen Petitions; Petition for Reconsideration or Stay of Action; Advisory Opinions—OMB Control Number 0910–0183—Extension

The Administrative Procedures Act (5 U.S.C. 553(e)), provides that every Agency shall give an interested person the right to petition for issuance, amendment, or repeal of a rule. Section 10.30 (21 CFR 10.30) sets forth the format and procedures by which an interested person may submit to FDA, in accordance with § 10.20 (21 CFR 10.20) (submission of documents to Division of Dockets Management), a citizen petition requesting the Commissioner of FDA (the Commissioner) to issue, amend, or revoke a regulation or order, or to take or refrain from taking any other form of administrative action.

The Commissioner may grant or deny such a petition, in whole or in part, and may grant such other relief or take other action as the petition warrants. Respondents are individuals or households, State or local governments, not-for-profit institutions or groups.

Section 10.33 (21 CFR 10.33) issued under section 701(a) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 371(a)), sets forth the format and procedures by which an interested person may request reconsideration of part or all of a decision of the Commissioner on a petition submitted under 21 CFR 10.25 (initiation of administrative